The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. (September 2019)

• Record Type: Journal Article
• Authors: Tucci, Marco; Passarelli, Anna; Todisco, Annalisa; Mannavola, Francesco; Stucci, Luigia Stefania; D'Oronzo, Stella; Rossini, Michele; Taurisano, Marco; Gesualdo, Loreto; Silvestris, Franco
• Is Part Of: Therapeutic advances in medical oncology. Volume 11(2019)
• Publication Date: 2019-09
• Subjects: acute interstitial nephritis -- immunotherapy -- melanoma -- nephrotoxicity; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758835919875549
• Languages: English
• ISSNs: 1758-8340

Abstract

Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of patients with a number of types of cancer, but the frequent development of immune-related adverse effects (irAEs) can worsen the outcome. The most common irAEs involve the gastrointestinal, cutaneous, and endocrine systems, but nephrotoxicity, resulting from damage to the tubule-interstitial compartment, may occur in some patients. The early phases of acute interstitial nephritis (AIN) are characterized by systemic symptoms that indicate a poor clinical state as well as a mild deterioration of renal function. Tubular injury is due to a direct effect mediated by cytotoxic CD8 + T cells, which sustain the local production of pro-inflammatory cytokines that progressively impair renal function. The treatment of AIN is mainly based on high-dose steroids, which in most instances leads to the recovery of renal function. However, the premature discontinuation of ICI therapy may prevent the impact of treatment on the clinical progression of the malignancy. Adequately addressing irAEs requires a standardized therapy that is based on the results of large clinical trials.